Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1616
interventional 1177
Observational 404
Registry 35

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 315
Drug|placebo 217
Behavioral 173
Other 166
Device 73
Biological 50
Procedure 25
Biological|placebo 20
Device|Other 18
Behavioral|Other 17
Dietary Supplement 12
Biological|Drug 9
Diagnostic Test 9
Drug|Procedure 8
Behavioral|placebo 7
Dietary Supplement|placebo 7
Behavioral|Device 6
Other|placebo 5
Device|Procedure 4
Drug|Other 4
Biological|Drug|placebo 3
Device|Drug 3
Radiation 3
Biological|Other 2
Dietary Supplement|Drug|placebo 2
Dietary Supplement|Other 2
Behavioral|Combination Product 1
Behavioral|Device|Dietary Supplement|Other 1
Behavioral|Device|Other 1
Behavioral|Drug 1
Behavioral|Drug|placebo|Procedure 1
Biological|Device|Other 1
Biological|Drug|Other 1
Biological|Drug|Other|placebo 1
Biological|Drug|Other|Procedure 1
Biological|Procedure 1
Combination Product 1
Device|Diagnostic Test 1
Dietary Supplement|Drug 1
Drug|Other|Procedure 1
Genetic|Other 1
Other|Procedure 1
placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 426
NA 87
France 67
United Kingdom 54
Canada 46
Italy 38
Germany 34
Belgium 27
Turkey 26
United States|Canada 24
Spain 20
Denmark 17
Switzerland 15
Iran, Islamic Republic of 11
Israel 11
Australia 10
Sweden 10
Norway 7
Japan 6
Ireland 5
Russian Federation 5
China 4
Netherlands 4
Brazil 3
Greece 3
Jordan 3
Australia|New Zealand 2
Austria|Belgium|Canada|Czech Republic|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Norway|Poland|Portugal|Slovenia|Spain|Sweden|Switzerland|United Kingdom 2
Canada|France 2
Croatia 2
Czech Republic 2
Czech Republic|Germany|Hungary|India|Poland|Russian Federation|Ukraine|United Kingdom 2
Czech Republic|Russian Federation|Ukraine 2
Ireland|United Kingdom 2
Lebanon 2
Mexico 2
Slovenia 2
United States|Austria|Canada|Chile|Czech Republic|Denmark|Estonia|Finland|France|Germany|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Sweden|Switzerland|Turkey|Ukraine|United Kingdom 2
United States|Belarus|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Finland|France|Georgia|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Mexico|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Turkey|Ukraine|United Kingdom 2
United States|Belgium|Bulgaria|Czechia|Germany|Kuwait|Latvia|Lebanon|Poland|Turkey 2
United States|Canada|Finland|Germany|Hungary|Italy|Norway|Poland|Russian Federation|Spain|Switzerland|Turkey 2
United States|Canada|Puerto Rico 2
United States|Honduras 2
United States|Puerto Rico 2
United States|Russian Federation|Ukraine 2
United States|Spain 2
United States|United Kingdom 2
Argentina|Australia|Austria|Belgium|Bulgaria|Canada|Croatia|Czech Republic|Estonia|Finland|France|Germany|Greece|Israel|Italy|Latvia|Lebanon|Morocco|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Serbia|Slovakia|Spain|Turkey 1
Argentina|Austria|Belgium|Bulgaria|Canada|Croatia|Czech Republic|Estonia|Finland|France|Germany|Greece|Israel|Italy|Latvia|Lebanon|Morocco|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Spain 1
Argentina|Brazil|Colombia|Jordan|Malaysia|Mexico|Panama|Peru 1
Argentina|Chile|Spain 1
Australia|Austria|Canada|Finland|France|Germany|Italy|Netherlands|New Zealand|Norway|Poland|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Canada|Czech Republic|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Netherlands|Poland|Romania|Russian Federation|Slovakia|South Africa|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|Belgium|Canada|Czech Republic|Finland|France|Germany|Greece|Israel|Lithuania|Netherlands|Poland|Russian Federation|Slovakia|South Africa|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|Belgium|Czechia|Denmark|Estonia|Finland|France|Germany|Ireland|Italy|Netherlands|Norway|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|Belgium|Czechia|France|Germany|Hungary|Italy|Netherlands|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Denmark|France|Germany|Italy|Netherlands|Portugal|United Kingdom 1
Australia|Spain 1
Australia|Sweden 1
Australia|United States|Austria|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|France|Germany|Greece|India|Ireland|Israel|Italy|Latvia|Mexico|Moldova, Republic of|Netherlands|New Zealand|North Macedonia|Poland|Puerto Rico|Romania|Serbia|Slovakia|South Africa|Spain|Switzerland|Ukraine|United Kingdom 1
Austria 1
Austria|Belgium|Bulgaria|Czechia|France|Germany|Greece|Italy|Netherlands|Poland|Portugal|Russian Federation|Spain|Turkey|United Kingdom 1
Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Norway|Poland|Portugal|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Canada|Czechia|France|Hungary|Italy|Portugal|Slovakia|Slovenia|Spain 1
Austria|Belgium|Czechia|Denmark|Finland|France|Greece|Hungary|Italy|Lithuania|Netherlands|Norway|Poland|Portugal|Slovakia|Spain|Sweden|United Kingdom 1
Austria|Canada|Germany|Russian Federation|Ukraine 1
Austria|Denmark|Estonia|Finland|Germany|Italy|Latvia|Lithuania|Netherlands|Norway|Portugal|Switzerland 1
Belarus|Bosnia and Herzegovina|Bulgaria|Croatia|Moldova, Republic of|Poland|Serbia 1
Belarus|Croatia|Georgia|Moldova, Republic of|Poland|Serbia|Ukraine 1
Belgium|Bulgaria|Canada|Croatia|Czech Republic|Finland|Germany|Hungary|Italy|Lithuania|Poland|Russian Federation|Serbia|Spain|Switzerland|Turkey|Ukraine|United Kingdom 1
Belgium|Bulgaria|Canada|Croatia|Czech Republic|Finland|Germany|Hungary|Italy|Lithuania|Poland|Russian Federation|Serbia|Spain|Turkey|Ukraine|United Kingdom 1
Belgium|Canada|Finland|France|Guatemala|Poland|Spain|Switzerland|United Kingdom 1
Belgium|Canada|Italy|Netherlands|Sweden|United Kingdom 1
Belgium|Czech Republic|Denmark|Norway|Sweden 1
Belgium|Denmark|Finland|Netherlands|Norway|Sweden|Switzerland|United Kingdom 1
Belgium|France|Germany|Italy|Spain 1
Belgium|Germany|Italy 1
Belgium|Germany|Netherlands 1
Belgium|Germany|Poland|Russian Federation|Spain 1
Belgium|Luxembourg|United Kingdom 1
Belgium|Mexico|Poland|Romania|Saudi Arabia|Ukraine 1
Bulgaria 1
Bulgaria|Canada|Czech Republic|Germany|Spain|Sweden|Ukraine|United Kingdom 1
Bulgaria|Croatia|Czechia|Estonia|Germany|Hungary|Italy|Poland|Russian Federation|Serbia|Spain|Ukraine 1
Bulgaria|Czechia|Poland|Russian Federation|Serbia|Slovakia|Spain|Ukraine 1
Bulgaria|France|Germany|Greece|Poland|Romania|Spain 1
Bulgaria|Poland|Romania|Ukraine 1
Bulgaria|Poland|Russian Federation|Serbia|Slovakia|Ukraine 1
Canada|Denmark|Estonia|Finland|Germany|Latvia|Netherlands|Spain|Sweden|United Kingdom 1
Canada|Denmark|Finland|France|Germany|Italy|Poland|Portugal|Spain|Switzerland|United Kingdom 1
Canada|Denmark|France|Germany|Italy|Poland|Portugal|Spain|Switzerland|United Kingdom 1
Chile 1
Colombia|Mexico 1
Croatia|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Denmark|France|Germany|Hungary|Italy|Kuwait|Lebanon|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Czech Republic|Germany|Hungary|Netherlands|Poland|Russian Federation|Sweden|Switzerland|Turkey|United Kingdom 1
Czechia 1
Czechia|Denmark|Estonia|Finland|France|Ireland|Italy|Netherlands|Norway|Spain|Sweden|United Kingdom 1
Czechia|France|Germany|Italy|Poland 1
Czechia|Germany|Hungary|Poland|Spain 1
Czechia|Germany|Poland 1
Czechia|Japan|Korea, Republic of|Poland|Taiwan 1
Denmark|Netherlands|Norway|Sweden 1
Denmark|Norway|Sweden 1
Egypt 1
Estonia|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Latvia|Lithuania|Mexico|Netherlands|Peru|Poland|Portugal|Russian Federation|Serbia|Slovakia|South Africa|Spain|Switzerland|Tunisia|Ukraine|United Kingdom 1
Finland 1
France|Belgium|Netherlands|Spain 1
France|Germany 1
France|Germany|Martinique|Switzerland|Turkey|United Kingdom 1
Germany|Australia|Austria|Belgium|Canada|Czech Republic|Denmark|Finland|Greece|Hungary|Ireland|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Germany|Australia|Austria|Canada|Czechia|Finland|France|Hungary|Israel|Italy|Poland|Spain|Sweden|United Kingdom 1
Germany|Italy 1
Germany|Poland 1
Germany|Poland|United Kingdom 1
Germany|Spain 1
Germany|Sweden 1
Germany|Switzerland 1
Hong Kong 1
Hungary 1
Hungary|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Latvia|Netherlands|Norway|Poland|Russian Federation|Slovenia|Spain|Sweden|Switzerland|Ukraine 1
India 1
India|Czechia|Germany|Hungary|Poland|Russian Federation|Ukraine|United Kingdom 1
India|United States|Belgium|Bulgaria|Canada|Chile|Colombia|Croatia|Czech Republic|Estonia|France|Georgia|Germany|Greece|Latvia|Mexico|Netherlands|New Zealand|Peru|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
Italy|Belgium|Canada|Czech Republic|France|Germany|Greece|Hungary|Poland|Spain|Switzerland|Tunisia|United Kingdom 1
Italy|Latvia|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Netherlands|Norway|Poland|Russian Federation|Slovenia|Spain|Sweden|Switzerland|Ukraine 1
Italy|Switzerland 1
Italy|United States|Australia|Belgium|Canada|France|Germany|Israel|Netherlands|Spain|United Kingdom 1
Japan|Russian Federation 1
Netherlands|United States|Canada|Czechia|Estonia|France|Russian Federation|Spain|Ukraine 1
New Zealand 1
Panama 1
Philippines 1
Poland 1
Poland|United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Denmark|Germany|Israel|Italy|Mexico|Netherlands|Russian Federation|Spain|Sweden|Ukraine|United Kingdom 1
Poland|United States|Belarus|Bosnia and Herzegovina|Bulgaria|Croatia|Czech Republic|Estonia|Georgia|Germany|Italy|Mexico|Moldova, Republic of|Romania|Russian Federation|Serbia|South Africa|Ukraine|United Kingdom 1
Portugal 1
Russian Federation|United Kingdom 1
Russian Federation|United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Croatia|Czech Republic|Denmark|Estonia|Finland|France|Germany|Greece|Italy|Latvia|Lebanon|Lithuania|Morocco|Netherlands|Poland|Portugal|Saudi Arabia|Serbia|Switzerland|Tunisia|Turkey|Ukraine|United Kingdom 1
Saudi Arabia 1
Serbia 1
Sweden|United States|Canada|Germany|Italy|Spain 1
Ukraine|United States|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Croatia|Estonia|Georgia|Germany|Greece|Hungary|Italy|Latvia|Lithuania|Moldova, Republic of|New Zealand|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czech Republic|Denmark|France|Germany|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Serbia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|Denmark|France|Germany|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Serbia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|Egypt|Estonia|Finland|France|Germany|Greece|Guatemala|Hungary|Ireland|Israel|Italy|Jordan|Korea, Republic of|Malaysia|Netherlands|Norway|Panama|Peru|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Egypt|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Portugal|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Bulgaria|Canada|China|Czechia|Estonia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Latvia|Lithuania|Netherlands|Poland|Portugal|Romania|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Bulgaria|Canada|Croatia|Czechia|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|India|Israel|Japan|Latvia|Lithuania|Mexico|Netherlands|Norway|Peru|Poland|Portugal|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Bulgaria|Canada|Croatia|Czechia|Finland|France|Germany|Hungary|India|Italy|Latvia|Lithuania|Mexico|Norway|Peru|Poland|Portugal|Russian Federation|Slovakia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Bulgaria|Canada|Croatia|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|India|Israel|Italy|Mexico|Netherlands|Poland|Puerto Rico|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Thailand|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Bulgaria|Croatia|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Kuwait|Portugal|Russian Federation|Saudi Arabia|Serbia|Slovakia|Spain|Tunisia|Turkey 1
United States|Argentina|Australia|Brazil|Canada|Croatia|Czech Republic|France|Germany|Mexico|Poland|Russian Federation|Serbia|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|Czech Republic|Denmark|Finland|France|Georgia|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Mexico|Moldova, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Argentina|Austria|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|Finland|France|Georgia|Germany|India|Italy|Korea, Republic of|Lebanon|Macedonia, The Former Yugoslav Republic of|Norway|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Arab Emirates|United Kingdom 1
United States|Argentina|Austria|Belgium|Croatia|Finland|France|Germany|Ireland|Italy|Mexico|Poland|Puerto Rico|Russian Federation|Spain|Turkey 1
United States|Argentina|Austria|Brazil|France|Germany|Italy|Netherlands|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Argentina|Belarus|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Croatia|Czechia|France|Germany|Ireland|Italy|Mexico|Norway|Poland|Russian Federation|Slovakia|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Czechia|Poland|Spain 1
United States|Australia 1
United States|Australia|Austria|Belarus|Belgium|Canada|Chile|China|Czech Republic|Estonia|France|Germany|Greece|Mexico|Netherlands|Philippines|Poland|Romania|Slovakia|Spain|Sweden|Thailand|Tunisia|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belarus|Brazil|Bulgaria|Canada|Croatia|Estonia|France|Germany|Italy|Latvia|Lithuania|Mexico|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Serbia|Slovakia|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bosnia and Herzegovina|Canada|Croatia|Czech Republic|France|Germany|Greece|Guatemala|India|Israel|Italy|Macedonia, The Former Yugoslav Republic of|Mexico|Moldova, Republic of|Netherlands|New Zealand|Poland|Romania|Serbia|Slovakia|South Africa|Switzerland|Ukraine|United Kingdom|Virgin Islands (U.S.) 1
United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Colombia|Croatia|Egypt|France|Georgia|Germany|Hungary|Ireland|Italy|Mexico|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Czechia|Finland|France|Germany|Greece|Hungary|Israel|Italy|Lithuania|Mexico|Netherlands|New Zealand|Norway|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Switzerland|Ukraine|United Kingdom|Uruguay 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czech Republic|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|Estonia|Finland|France|Georgia|Germany|Italy|Korea, Republic of|Lithuania|Norway|Poland|Portugal|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Chile|Czech Republic|Denmark|Estonia|Finland|France|Germany|Hungary|Lithuania|Mexico|Poland|Romania|Russian Federation|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|Poland|Romania|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Germany|Hungary|Italy|Poland|Spain|Sweden|Turkey|United Kingdom 1
United States|Austria|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|France|Georgia|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Latvia|Moldova, Republic of|Montenegro|North Macedonia|Poland|Romania|Russian Federation|Serbia|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|Belgium|Canada|Chile|Finland|France|Germany|Greece|Italy|Norway|Spain|Sweden|United Kingdom 1
United States|Austria|Belgium|France|Germany|Israel|Italy 1
United States|Austria|Bulgaria|Canada|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Austria|Bulgaria|Czechia|Estonia|Latvia|Lithuania|Russian Federation|Spain 1
United States|Austria|Canada|Czech Republic|Germany|Greece|Hungary|Israel|Poland|Slovakia|Sweden|United Kingdom 1
United States|Austria|Canada|Germany|Italy|Spain|United Kingdom 1
United States|Austria|Canada|Germany|Italy|United Kingdom 1
United States|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Costa Rica|Croatia|Czech Republic|Estonia|France|Germany|Greece|India|Ireland|Israel|Latvia|Macedonia, The Former Yugoslav Republic of|Mexico|Moldova, Republic of|New Zealand|Poland|Puerto Rico|Romania|Serbia|Slovakia|Spain|Ukraine 1
United States|Belarus|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|Georgia|Germany|Hungary|Latvia|Lithuania|Moldova, Republic of|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Chile|Colombia|Croatia|Czech Republic|Estonia|France|Georgia|Germany|Greece|India|Latvia|Mexico|Netherlands|New Zealand|Peru|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|China|Estonia|France|Greece|Israel|Lebanon|Lithuania|Morocco|Netherlands|North Macedonia|Portugal|Russian Federation|Serbia|Slovenia|Spain|Tunisia|Turkey|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Kuwait|Poland|Serbia|Spain|Sweden|Turkey|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Italy|Mexico|Romania|Russian Federation|Serbia|Slovakia|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Germany|Poland|Russian Federation|Serbia|Spain|Ukraine 1
United States|Belgium|Bulgaria|Georgia|Greece|Hungary|Italy|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine 1
United States|Belgium|Bulgaria|Kuwait|Lithuania|Poland|Turkey 1
United States|Belgium|Canada|Czech Republic|France|Germany|Netherlands|United Kingdom 1
United States|Belgium|Canada|Czech Republic|Germany|Greece|Japan|Poland|Russian Federation|Spain|Ukraine 1
United States|Belgium|Canada|Czechia|France|Poland|Portugal|Russian Federation 1
United States|Belgium|Canada|Poland 1
United States|Bosnia and Herzegovina|Brazil|Canada|Colombia|Costa Rica|Czechia|Denmark|Egypt|France|Germany|Guatemala|Hungary|Ireland|Italy|Lebanon|Mexico|Morocco|Netherlands|Panama|Poland|Russian Federation|Spain|United Arab Emirates 1
United States|Bulgaria|Canada|Czechia|Denmark|Germany|Italy|Netherlands|Norway|Russian Federation|Spain 1
United States|Bulgaria|Croatia|Czech Republic|Estonia|Georgia|Germany|Israel|Italy|Lithuania|Macedonia, The Former Yugoslav Republic of|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|South Africa|Spain|Ukraine 1
United States|Bulgaria|Czech Republic|Finland|Italy|Lithuania|Netherlands|Poland|Russian Federation|Serbia|United Kingdom 1
United States|Bulgaria|Czechia|France|Germany|Hungary|Israel|Poland|Romania|Russian Federation|Serbia|Slovakia|Ukraine 1
United States|Bulgaria|Estonia|Georgia|Moldova, Republic of|Russian Federation|Ukraine 1
United States|Canada|Czech Republic|France|Hungary|Italy|Netherlands|Poland|Russian Federation|Serbia|Spain|United Kingdom 1
United States|Canada|Czechia|Estonia|France|Netherlands|Russian Federation|Slovakia|Spain|Ukraine 1
United States|Canada|Estonia|Latvia|Ukraine 1
United States|Canada|Finland|France|Germany|Norway|Spain 1
United States|Canada|Germany|Italy|Netherlands|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Canada|Germany|Italy|Spain 1
United States|Canada|Germany|Netherlands|United Kingdom 1
United States|Canada|Germany|Sweden 1
United States|Colombia|Estonia|Hungary|Jordan|Korea, Republic of|Malaysia|Taiwan|Thailand|Turkey 1
United States|Croatia|Poland|Russian Federation|United Kingdom 1
United States|Czech Republic|Hungary|Poland 1
United States|Georgia|Poland 1
United States|Germany 1
United States|Germany|Poland 1
United States|Germany|Spain 1
United States|Israel 1
United States|Italy|Poland 1
United States|Italy|Russian Federation|Spain 1
United States|Poland|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Georgia|Greece|Hungary|Italy|Moldova, Republic of|Romania|Russian Federation|Serbia|Slovakia|South Africa|Spain|Ukraine|United Kingdom 1
United States|Poland|Bulgaria|Croatia|Czechia|Estonia|Georgia|Germany|Hungary|Israel|Italy|Lithuania|Romania|Russian Federation|South Africa|Ukraine|United Kingdom 1
United States|Poland|Spain|Ukraine 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 744
2 80
3 31
4 18
5 15
6 12
7 9
8 5
9 4
10 13
11 9
12 7
13 6
14 7
15 6
16 10
17 12
18 3
19 4
20 4
21 5
22 6
23 3
25 3
26 7
28 3
29 1
30 5
31 2
32 1
33 3
34 3
35 2
36 2
37 4
38 3
39 2
40 3
42 3
43 1
44 1
46 1
47 2
48 4
49 2
50 2
53 2
54 3
55 1
56 1
57 2
58 1
59 2
60 3
61 3
62 1
63 2
64 1
65 1
67 2
68 2
70 1
71 2
72 4
77 1
79 1
80 1
81 1
82 1
84 2
86 2
87 1
88 2
90 1
92 2
94 1
97 1
98 1
99 1
101 2
105 1
113 1
115 3
116 1
117 1
123 1
127 1
131 2
133 1
140 1
141 1
149 2
151 1
159 2
160 1
162 1
163 1
165 1
169 1
170 1
176 2
178 1
182 1
184 2
191 1
193 2
197 1
199 2
220 1
224 1
230 1
244 1
248 1
259 1
284 1
290 1
292 1
299 1
314 1
457 1

Phase

Phase Study_Count
N/A 485
Phase 2 192
Phase 3 189
Phase 4 129
Phase 1 97
Phase 1/Phase 2 53
Phase 2/Phase 3 26
Early Phase 1 6

Number of Arms

Number_of_Arms Count_of_Studies
1 232
2 639
3 143
4 61
5 12
6 15
7 1
8 4
9 2
25 1
NA 67

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 12.00 1.00000 3.00 3.00000 9.0000 20.0000 8.000 3.0000
1st Qu. 12.75 28.00000 17.75 18.00000 32.0000 50.7500 140.000 40.0000
Median 22.50 45.00000 26.00 30.00000 64.0000 65.5000 264.000 90.0000
Mean 30.00 88.03512 39.25 41.03846 641.9634 117.8077 554.709 266.1163
3rd Qu. 30.75 88.00000 48.00 52.50000 177.0000 104.5000 900.000 261.0000
Max. 80.00 2500.00000 264.00 250.00000 100000.0000 596.0000 4125.000 6998.0000

Trial Group Type

group_type Group_Count
Experimental 1374
Active Comparator 485
Placebo Comparator 272
No Intervention 130
Other 121
NA 67
Sham Comparator 33

Intervention Model

intervention_model Study_Count
Parallel Assignment 734
Single Group Assignment 286
Crossover Assignment 109
Factorial Assignment 19
NA 18
Sequential Assignment 11

Primary Purpose

primary_purpose Study_Count
Treatment 879
Other 71
Supportive Care 65
Basic Science 41
Diagnostic 35
Prevention 32
NA 27
Health Services Research 17
Screening 7
Device Feasibility 3

Observational Studies

Studies by Country

Country Study_Count
United States 147
NA 38
France 36
Germany 19
Canada 17
United Kingdom 15
Switzerland 14
Turkey 13
Finland 9
Argentina 8
Italy 6
Poland 5
Egypt 4
Greece 4
Israel 4
United States|Canada 4
Denmark 3
Spain 3
Taiwan 3
Belgium 2
China 2
Korea, Republic of 2
United States|Puerto Rico 2
Albania|Algeria|Argentina|Belgium|Czechia|Egypt|France|Germany|Greece|Hungary|Israel|Kazakhstan|Netherlands|Portugal|Saudi Arabia|Tunisia|Turkey 1
Argentina|Algeria|Bahrain|Bulgaria|Egypt|Hungary|Iran, Islamic Republic of|Korea, Republic of|Kuwait|Lebanon|Morocco|Poland|Saudi Arabia 1
Argentina|Australia|Belgium|Brazil|Canada|Czechia|Finland|France|Germany|Greece|Italy|Mexico|Netherlands|Norway|Portugal|Slovakia|Spain|United Kingdom 1
Argentina|Bahrain|Belgium|Bosnia and Herzegovina|Canada|China|Colombia|Czech Republic|Egypt|Estonia|France|Germany|Iran, Islamic Republic of|Israel|Italy|Jordan|Korea, Republic of|Kuwait|Lebanon|Libyan Arab Jamahiriya|Mexico|Netherlands|New Zealand|Norway|Pakistan|Portugal|Saudi Arabia|Singapore|Slovakia|Slovenia|Sweden|Syrian Arab Republic|Taiwan|United Arab Emirates|United Kingdom|Venezuela 1
Australia 1
Australia|Austria|Bahrain|Belgium|Canada|Colombia|Czech Republic|Denmark|Egypt|France|Germany|Greece|Indonesia|Israel|Italy|Jordan|Kazakhstan|Korea, Republic of|Kuwait|Lebanon|Mexico|Netherlands|Norway|Oman|Portugal|Slovenia|Spain|Sweden|Switzerland|Taiwan|Thailand|United Arab Emirates|United Kingdom 1
Australia|Denmark|Finland|New Zealand|Norway|Sweden 1
Austria|Belgium|Bosnia and Herzegovina|Croatia|Czechia|France|Greece|Hungary|Italy|Spain|Switzerland 1
Austria|Belgium|Brazil|Bulgaria|Chile|Colombia|Dominican Republic|Egypt|Italy|Kuwait|Montenegro|Netherlands|Panama|Paraguay|Poland|Portugal|Qatar|Romania|Russian Federation|Saudi Arabia|Slovakia|Spain|Turkey|United Arab Emirates|United Kingdom 1
Austria|Belgium|Canada|Czech Republic|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Norway|Poland|Slovenia|Spain|Sweden|Switzerland 1
Austria|Belgium|Finland|Germany|Israel|United Kingdom 1
Austria|Denmark|Norway|Sweden 1
Belgium|Czechia 1
Brazil 1
Colombia 1
Czech Republic 1
Czech Republic|France|Germany|Iran, Islamic Republic of|Israel|Italy|Jordan|Korea, Republic of|Lebanon|Netherlands|Portugal|Saudi Arabia|Spain|Taiwan|Turkey 1
Czech Republic|Switzerland 1
Denmark|France|Germany|Netherlands|Norway|Portugal|Slovakia|Sweden|Switzerland|United Kingdom 1
France|Argentina|Canada|Czechia|Germany|Ireland|Israel|Lebanon|Netherlands|Norway|Portugal|Spain|United Arab Emirates 1
France|Martinique 1
France|Spain|Switzerland 1
Iran, Islamic Republic of 1
Ireland 1
Italy|Romania 1
Japan 1
Netherlands 1
Norway 1
Portugal 1
Russian Federation 1
Slovakia 1
Slovenia 1
Sweden 1
United States|Argentina|Australia|Austria|Belgium|Canada|Cyprus|Czechia|Denmark|Finland|France|Germany|Greece|Ireland|Italy|Lebanon|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|United Arab Emirates|United Kingdom 1
United States|Argentina|Australia|Austria|France|Germany|Israel|Italy|Norway|Spain|Turkey|United Kingdom 1
United States|Argentina|Australia|Canada|Chile|Mexico|Puerto Rico 1
United States|Argentina|Australia|Canada|Croatia|Czech Republic|France|Germany|Hungary|Italy|Spain|Switzerland|United Kingdom 1
United States|Argentina|Canada|France|Italy|Russian Federation|Tunisia|Venezuela 1
United States|Australia|Austria|Canada 1
United States|Australia|Austria|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Portugal|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|Czechia|Denmark|Germany|Italy|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
United States|Canada|Czechia|France|Italy|Sweden|Switzerland|United Kingdom 1
United States|Germany 1
United States|Israel 1

Sites per Study

Site_count Study_Count
1 310
2 8
3 8
4 7
5 7
6 6
7 2
8 2
9 1
10 4
11 4
12 1
13 2
14 2
15 1
16 1
17 3
18 3
19 1
23 2
27 2
28 4
30 1
31 1
33 1
36 1
41 1
43 2
44 2
47 1
48 1
49 1
50 1
58 1
62 1
64 1
121 1
152 1
168 1
181 1
251 1
422 1
478 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 50.5000
Median 110.0000
Mean 936.2084
3rd Qu 280.0000
Max 120000.0000

Observation Model

observational_model Study_Count
Cohort 243
Case-Control 52
Case-Only 38
Case Control 26
Other 20
NA 18
Case-Crossover 4
Defined Population, Natural History 2
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 285
Cross-Sectional 44
Retrospective 43
NA 17
Other 13
Cross-Sectional, Retrospective 1
Longitudinal, Retrospective/Prospective 1

Registries

Studies by Country

Country Study_Count
United States 5
France 4
NA 4
Turkey 4
Denmark 2
France|Martinique 2
Argentina 1
China 1
Czechia 1
Egypt 1
Greece 1
Lebanon 1
Sweden 1
Switzerland 1
United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Czechia|Denmark|France|Germany|Hungary|Ireland|Italy|Netherlands|New Zealand|Norway|Poland|Portugal|Puerto Rico|Slovakia|Spain|Switzerland|United Kingdom 1
United States|Australia|France|Germany|Ireland|Italy|Poland|Spain|United Kingdom 1
United States|Austria|Belgium|Canada|Denmark|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Canada 1
United States|Italy 1

Sites per Study

Site_count Study_Count
1 25
2 2
3 1
10 1
15 1
18 1
30 1
34 1
38 1
394 1

Enrollment Metrics

Measure Registries
Min 25.0
1st Qu 88.0
Median 325.0
Mean 174962.1
3rd Qu 3763.0
Max 5940299.0

Registry Model

observational_model Study_Count
Cohort 26
Other 6
Case-Control 1
Case-Only 1
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 28
Cross-Sectional 3
Other 3
NA 1

Follow-up

target_duration Study_Count
2 Years 5
1 Day 4
1 Year 4
5 Years 3
3 Years 2
52 Weeks 2
1 Month 1
10 Months 1
10 Years 1
12 Months 1
15 Years 1
17 Years 1
2 Months 1
20 Months 1
24 Months 1
24 Years 1
25 Years 1
3 Months 1
30 Years 1
5 Days 1
8 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04283747 Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04283747 Recruiting Mazandaran University of Medical Sciences 2022-10-31
NCT02301572 Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course https://ClinicalTrials.gov/show/NCT02301572 Completed Weill Medical College of Cornell University 2016-07-31
NCT03662347 Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP) https://ClinicalTrials.gov/show/NCT03662347 Recruiting Central Hospital, Nancy, France 2022-03-31
NCT03408093 Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b https://ClinicalTrials.gov/show/NCT03408093 Completed Bayer 2010-03-30
NCT03401307 Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03401307 Active, not recruiting University of Southern Denmark 2020-07-31
NCT03396822 Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03396822 Recruiting University of Maryland, Baltimore 2020-09-30
NCT03368677 Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression https://ClinicalTrials.gov/show/NCT03368677 Recruiting Turku University Hospital 2022-11-30
NCT03368157 PREG-MS: New England MS Pregnancy Registry https://ClinicalTrials.gov/show/NCT03368157 Recruiting Brigham and Women’s Hospital 2019-04-07
NCT03975413 Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03975413 Active, not recruiting Rush University Medical Center 2020-04-01
NCT03826095 Respiratory Functions, Trunk Control and Mobility Evaluation in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03826095 Completed Hacettepe University 2019-07-26
NCT03825055 Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03825055 Recruiting Universita di Verona 2022-03-31
NCT03313843 Study to Assess OCT: RNFL and GCL in MS Patients https://ClinicalTrials.gov/show/NCT03313843 Recruiting Tampa Bay Uveitis Center, LLC 2022-12-31
NCT03302442 Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03302442 Completed Nantes University Hospital 2017-08-01
NCT03291756 Corrona Multiple Sclerosis (MS) Registry https://ClinicalTrials.gov/show/NCT03291756 Enrolling by invitation Corrona, LLC. 2100-12-31
NCT03284970 Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes https://ClinicalTrials.gov/show/NCT03284970 Completed EMD Serono 2018-05-11
NCT03281330 Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS) https://ClinicalTrials.gov/show/NCT03281330 Completed Hasselt University 2018-05-30
NCT03268096 Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination https://ClinicalTrials.gov/show/NCT03268096 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2020-12-31
NCT03255460 The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03255460 Completed Gazi University 2018-07-04
NCT03250169 Neurofilaments for NEDA Assessing in MS https://ClinicalTrials.gov/show/NCT03250169 Recruiting Queen Mary University of London 2020-07-01
NCT03217396 Biomarkers of Synaptic Damage in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03217396 Recruiting Neuromed IRCCS 2020-09-01
NCT03216915 Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03216915 Recruiting Universitätsklinikum Hamburg-Eppendorf 2019-12-31
NCT03209479 Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) “Prevention of Relapse of Multiple Sclerosis” https://ClinicalTrials.gov/show/NCT03209479 Recruiting Takeda 2025-03-31
NCT03205280 Clinical Decision Support System (CADIMS) for MS Diagnostic https://ClinicalTrials.gov/show/NCT03205280 Recruiting Rennes University Hospital 2020-03-01
NCT03204747 Effect of Need to Void on Gait Speed in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03204747 Completed Pierre and Marie Curie University 2017-08-31
NCT03191669 Vaccine Exposure in Patients With MS https://ClinicalTrials.gov/show/NCT03191669 Completed Hospices Civils de Lyon 2017-07-07
NCT03164018 Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis https://ClinicalTrials.gov/show/NCT03164018 Completed Genesis Pharma CNS & Specialty 2018-12-15
NCT03157830 Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab https://ClinicalTrials.gov/show/NCT03157830 Recruiting Providence Health & Services 2021-06-30
NCT03151941 Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study https://ClinicalTrials.gov/show/NCT03151941 Completed Solent NHS Trust 2017-08-31
NCT03135327 Clinical Applications of Advanced Ophthalmic Imaging https://ClinicalTrials.gov/show/NCT03135327 Recruiting University of Miami 2020-12-31
NCT03134573 Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study https://ClinicalTrials.gov/show/NCT03134573 Completed Bayer 2018-05-09
NCT03122873 Quantitation of McArdle’s Sign and Evaluation of Specificity for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03122873 Completed Mayo Clinic 2017-06-30
NCT03111394 Study of myMS in Participants With a Diagnosis of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03111394 Active, not recruiting University of Southern California 2020-12-31
NCT03108573 Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters https://ClinicalTrials.gov/show/NCT03108573 Completed Fondation Ophtalmologique Adolphe de Rothschild 2013-07-31
NCT03087136 A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil https://ClinicalTrials.gov/show/NCT03087136 Recruiting Pontificia Universidade Católica do Rio Grande do Sul 2019-03-31
NCT03066752 Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes https://ClinicalTrials.gov/show/NCT03066752 Completed The Hospital for Sick Children 2017-11-24
NCT03052595 Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance https://ClinicalTrials.gov/show/NCT03052595 Recruiting Slovak Academy of Sciences 2020-06-30
NCT03047460 Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting https://ClinicalTrials.gov/show/NCT03047460 Completed Clinique Neuro-Outaouais 2018-01-31
NCT03033355 Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder https://ClinicalTrials.gov/show/NCT03033355 Completed The Methodist Hospital System 2019-03-31
NCT03025269 Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03025269 Enrolling by invitation University at Buffalo 2021-04-30
NCT03004794 Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort https://ClinicalTrials.gov/show/NCT03004794 Completed Cairo University 2016-08-31
NCT03004079 Clinical Importance of Glucose Regulation in Relapsing MS https://ClinicalTrials.gov/show/NCT03004079 Recruiting University of Virginia 2020-09-30
NCT02994121 Prospective Investigation of Multiple Sclerosis in the Three Rivers Region https://ClinicalTrials.gov/show/NCT02994121 Recruiting University of Pittsburgh 2047-01-31
NCT02969304 Study of Utilization Patterns of Dimethyl Fumarate in Germany https://ClinicalTrials.gov/show/NCT02969304 Completed Biogen 2017-03-02
NCT02966808 Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02966808 Recruiting Hospital General Universitario Gregorio Marañon 2020-12-31
NCT02965170 Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS https://ClinicalTrials.gov/show/NCT02965170 Completed Rocky Mountain MS Research Group, LLC 2017-12-31
NCT02921035 Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02921035 Active, not recruiting Merck KGaA, Darmstadt, Germany 2020-06-30
NCT02913209 Quantitative Fatigue and Muscle Performance in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02913209 Active, not recruiting Washington D.C. Veterans Affairs Medical Center 2018-10-31
NCT02907281 Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02907281 Completed Novartis 2017-07-24
NCT02896933 Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02896933 Completed Fondation Ophtalmologique Adolphe de Rothschild 2015-01-31
NCT02898974 Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02898974 Completed Colorado State University 2017-10-31
NCT02893683 Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02893683 Completed Fondation Ophtalmologique Adolphe de Rothschild 2017-05-15
NCT02887352 French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02887352 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2020-01-31
NCT02869360 Correlation Between PET and Advanced MRI in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02869360 Completed University of British Columbia 2019-10-02
NCT02852317 Urinary Markers of Detrusor Overactivity in Spina Bifida Patients https://ClinicalTrials.gov/show/NCT02852317 Completed Rennes University Hospital 2017-03-29
NCT02845635 MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02845635 Recruiting Duke University 2025-08-31
NCT02814487 MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment. https://ClinicalTrials.gov/show/NCT02814487 Completed Ad scientiam 2016-09-30
NCT02799199 Fingolimod Real World Experience: the French Grand-Est Cohort https://ClinicalTrials.gov/show/NCT02799199 Completed CHU de Reims 2015-10-31
NCT02789670 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02789670 Recruiting University Hospital, Lille 2020-07-31
NCT02776072 Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02776072 Completed Biogen 2016-12-31
NCT02749396 EPID Multiple Sclerosis Pregnancy Study https://ClinicalTrials.gov/show/NCT02749396 Completed Bayer 2018-08-14
NCT02740296 Depression and Immune Function in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT02740296 Completed Charite University, Berlin, Germany 2017-06-30
NCT02736279 Impact of Tecfidera on Gut Microbiota https://ClinicalTrials.gov/show/NCT02736279 Recruiting EvergreenHealth 2020-06-30
NCT02695394 Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study https://ClinicalTrials.gov/show/NCT02695394 Completed Charite University, Berlin, Germany 2016-12-31
NCT02677077 Clinical Disease Activity With Long Term Natalizumab Treatment https://ClinicalTrials.gov/show/NCT02677077 Completed Biogen 2016-08-18
NCT02679885 Teriflunomide Male Transmission Study https://ClinicalTrials.gov/show/NCT02679885 Completed Griffin Hospital 2018-08-31
NCT02664324 MSPT Device Usability Study https://ClinicalTrials.gov/show/NCT02664324 Completed Biogen 2016-04-30
NCT02652091 Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction https://ClinicalTrials.gov/show/NCT02652091 Completed Bayer 2017-08-11
NCT02651545 Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02651545 Recruiting State University of New York at Buffalo 2020-11-15
NCT02623946 Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02623946 Active, not recruiting Clinique Neuro-Outaouais 2020-12-31
NCT02612935 An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02612935 Completed Lumos Labs, Inc. 2017-02-28
NCT02601131 Post-transfusion Platelet Count https://ClinicalTrials.gov/show/NCT02601131 Completed Region Skane 2016-09-30
NCT02588053 Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? https://ClinicalTrials.gov/show/NCT02588053 Completed University of Colorado, Denver 2018-12-31
NCT02592265 Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden https://ClinicalTrials.gov/show/NCT02592265 Completed Lille Catholic University 2015-08-31
NCT04145284 Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS https://ClinicalTrials.gov/show/NCT04145284 Completed Biogen 2020-04-30
NCT01617395 Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility https://ClinicalTrials.gov/show/NCT01617395 Completed National Institutes of Health Clinical Center (CC) NA
NCT00493298 Tysabri Observational Program https://ClinicalTrials.gov/show/NCT00493298 Active, not recruiting Biogen 2029-01-03
NCT02559765 Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK. https://ClinicalTrials.gov/show/NCT02559765 Completed University of Glasgow 2015-11-30
NCT02549703 Mitochondrial Dysfunction and Disease Progression https://ClinicalTrials.gov/show/NCT02549703 Completed Icahn School of Medicine at Mount Sinai 2018-09-27
NCT02519413 Tecfidera Lymphocyte Chart Review https://ClinicalTrials.gov/show/NCT02519413 Completed Biogen 2016-02-29
NCT02504840 Natural History of Multiple Sclerosis and Its Mimickers https://ClinicalTrials.gov/show/NCT02504840 Completed National Institutes of Health Clinical Center (CC) 2020-03-18
NCT02486640 Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon https://ClinicalTrials.gov/show/NCT02486640 Completed Bayer 2019-10-31
NCT02486562 iConquerMSâ„¢ - A Patient-Powered Research Network for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02486562 Recruiting Accelerated Cure Project for Multiple Sclerosis 2026-10-31
NCT02440126 Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk https://ClinicalTrials.gov/show/NCT02440126 Recruiting Rocky Mountain MS Research Group, LLC 2017-03-31
NCT02433028 Swiss Multiple Sclerosis Cohort-Study https://ClinicalTrials.gov/show/NCT02433028 Recruiting University Hospital, Basel, Switzerland 2042-01-31
NCT02418897 Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02418897 Completed Texas Tech University Health Sciences Center 2016-11-30
NCT02398149 Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02398149 Completed Mount Sinai Rehabilitation Hospital 2016-10-31
NCT02386566 Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab https://ClinicalTrials.gov/show/NCT02386566 Completed Biogen 2018-01-28
NCT02383550 Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension https://ClinicalTrials.gov/show/NCT02383550 Completed Clinique Neuro-Outaouais 2017-08-30
NCT02367222 A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrixâ„¢ in Manitoba, Canada https://ClinicalTrials.gov/show/NCT02367222 Completed University of Manitoba 2015-08-31
NCT02369224 Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics https://ClinicalTrials.gov/show/NCT02369224 Completed Brown, Theodore R., M.D., MPH 2016-02-29
NCT02346279 Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists https://ClinicalTrials.gov/show/NCT02346279 Completed Institut fuer Physiotherapieforschung 2013-10-31
NCT02330965 Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02330965 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-07-12
NCT02335892 PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod https://ClinicalTrials.gov/show/NCT02335892 Completed Novartis 2017-02-01
NCT02313285 A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 https://ClinicalTrials.gov/show/NCT02313285 Active, not recruiting Sanofi 2022-04-30
NCT02308670 Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02308670 Completed University at Buffalo 2016-10-31
NCT02308579 Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases https://ClinicalTrials.gov/show/NCT02308579 Completed University at Buffalo 2015-03-31
NCT02307877 Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate https://ClinicalTrials.gov/show/NCT02307877 Active, not recruiting University of Colorado, Denver 2020-03-31
NCT02287948 Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects https://ClinicalTrials.gov/show/NCT02287948 Completed University Hospital of Ferrara 2015-12-31
NCT02275741 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02275741 Completed University of Rostock 2015-09-30
NCT02277964 Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod https://ClinicalTrials.gov/show/NCT02277964 Completed University Hospital, Basel, Switzerland 2016-08-31
NCT02247310 BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon https://ClinicalTrials.gov/show/NCT02247310 Completed Bayer 2016-07-19
NCT02230969 Plegridy Observational Program https://ClinicalTrials.gov/show/NCT02230969 Active, not recruiting Biogen 2022-01-20
NCT02225977 Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. https://ClinicalTrials.gov/show/NCT02225977 Completed University of Southern California 2016-12-31
NCT02207075 Measuring Active Microglia in Progressive Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02207075 Active, not recruiting Weill Medical College of Cornell University 2020-06-30
NCT02159573 Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) https://ClinicalTrials.gov/show/NCT02159573 Completed Biogen 2015-01-31
NCT02157064 Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02157064 Active, not recruiting StemGenex 2019-05-31
NCT02142946 Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study https://ClinicalTrials.gov/show/NCT02142946 Recruiting University Hospital, Basel, Switzerland 2020-12-31
NCT02139696 Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation https://ClinicalTrials.gov/show/NCT02139696 Completed Turku University Hospital 2015-01-31
NCT02137109 Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri https://ClinicalTrials.gov/show/NCT02137109 Completed Biogen 2015-10-31
NCT02137707 Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya https://ClinicalTrials.gov/show/NCT02137707 Completed McGill University 2017-11-30
NCT02121444 BAY86-5046 (Betaseron), Non Interventional Studies https://ClinicalTrials.gov/show/NCT02121444 Completed Bayer 2016-03-09
NCT02118298 Allocentric Memory in MS and Resting State Functional MRI https://ClinicalTrials.gov/show/NCT02118298 Completed Yale University 2016-04-30
NCT02099370 Adherence to Treatment With Tecfideraâ„¢ in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02099370 Completed University of South Florida 2016-01-31
NCT02082002 Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino https://ClinicalTrials.gov/show/NCT02082002 Completed Ospedale Civico, Lugano 2018-12-21
NCT02076841 Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen https://ClinicalTrials.gov/show/NCT02076841 Completed Biogen 2016-02-29
NCT01285479 Pregnancy Registry Trial https://ClinicalTrials.gov/show/NCT01285479 Recruiting Novartis 2030-07-31
NCT01281657 Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program https://ClinicalTrials.gov/show/NCT01281657 Completed Novartis 2012-07-31
NCT01272128 Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study https://ClinicalTrials.gov/show/NCT01272128 Completed Biogen 2014-09-30
NCT01272596 Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01272596 Completed Charite University, Berlin, Germany 2013-11-30
NCT03360188 Pediatric Onset Multiple Sclerosis in Egyptians https://ClinicalTrials.gov/show/NCT03360188 Completed Cairo University 2015-12-31
NCT02047760 Neuroretinal Biomarkers in Neurodegenerative Diseases https://ClinicalTrials.gov/show/NCT02047760 Completed University of Edinburgh 2016-02-29
NCT04036097 Prospective Stratification of Infectious Risks in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04036097 Recruiting University Hospital, Basel, Switzerland 2022-04-30
NCT02017808 Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months https://ClinicalTrials.gov/show/NCT02017808 Completed University at Buffalo 2014-12-31
NCT03357887 Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome https://ClinicalTrials.gov/show/NCT03357887 Active, not recruiting Centre Hospitalier Universitaire de Nīmes 2020-12-31
NCT00794352 Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System https://ClinicalTrials.gov/show/NCT00794352 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02011204 Study of Electrical Impedance Myography (EIM) in ALS https://ClinicalTrials.gov/show/NCT02011204 Completed Skulpt, Inc. 2016-03-31
NCT02008669 Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02008669 Completed Lille Catholic University 2017-06-09
NCT01993004 Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells https://ClinicalTrials.gov/show/NCT01993004 Completed Rutgers, The State University of New Jersey 2015-12-31
NCT01977287 Walking With FES or AFO in People With MS With Foot Drop https://ClinicalTrials.gov/show/NCT01977287 Completed Queen Margaret University 2016-03-31
NCT01979081 Detecting and Addressing Preclinical Disability https://ClinicalTrials.gov/show/NCT01979081 Completed McMaster University 2017-06-30
NCT01945359 Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design https://ClinicalTrials.gov/show/NCT01945359 Completed Rocky Mountain MS Research Group, LLC 2014-09-30
NCT01943526 Ireland Natalizumab (TYSABRI) Observational Program https://ClinicalTrials.gov/show/NCT01943526 Completed Biogen 2017-12-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01909492 Relaxin in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01909492 Recruiting Providence Health & Services 2019-09-30
NCT01903291 Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS https://ClinicalTrials.gov/show/NCT01903291 Completed Biogen 2016-02-29
NCT01881191 Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months https://ClinicalTrials.gov/show/NCT01881191 Completed University at Buffalo 2015-10-31
NCT01851434 Natural History of Optic Neuritis https://ClinicalTrials.gov/show/NCT01851434 Completed National Institutes of Health Clinical Center (CC) 2014-09-05
NCT01847287 A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years https://ClinicalTrials.gov/show/NCT01847287 Completed University at Buffalo 2013-02-28
NCT01846234 Sodium Intake in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01846234 Completed Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia 2013-07-31
NCT01776060 Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study https://ClinicalTrials.gov/show/NCT01776060 Active, not recruiting Duke University 2020-12-31
NCT01774123 Optical Coherence Tomography in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01774123 Completed The Cleveland Clinic 2013-06-30
NCT01765361 Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG) https://ClinicalTrials.gov/show/NCT01765361 Completed University Hospital, Basel, Switzerland 2015-01-31
NCT01749943 Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01749943 Completed Brown, Theodore R., M.D., MPH 2013-07-31
NCT04185688 The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04185688 Completed Gazi University 2020-02-07
NCT01737372 A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01737372 Completed Rocky Mountain MS Research Group, LLC 2016-10-31
NCT01723709 The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort https://ClinicalTrials.gov/show/NCT01723709 Completed Duke University 2017-05-31
NCT01711255 Evaluation of Coagulation in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01711255 Completed Bastyr University 2016-05-31
NCT01704183 Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01704183 Completed Kuopio University Hospital 2014-03-31
NCT01703429 Complementary and Alternative Care in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01703429 Recruiting Bastyr University 2030-06-30
NCT01695434 A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months https://ClinicalTrials.gov/show/NCT01695434 Completed University at Buffalo 2013-02-28
NCT02659956 Pathological Basis of MRI Signal Changes in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02659956 Recruiting National Institutes of Health Clinical Center (CC) 2041-02-26
NCT01652352 Experimental Evaluation of Wheelchair-Mounted Robotic Arms https://ClinicalTrials.gov/show/NCT01652352 Completed University of South Florida 2011-07-31
NCT01626248 Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control https://ClinicalTrials.gov/show/NCT01626248 Completed Rocky Mountain MS Research Group, LLC 2013-03-31
NCT01628315 Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study https://ClinicalTrials.gov/show/NCT01628315 Completed University at Buffalo 2009-03-31
NCT01601119 Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients https://ClinicalTrials.gov/show/NCT01601119 Completed Merck KGaA, Darmstadt, Germany 2014-07-31
NCT01601080 An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device https://ClinicalTrials.gov/show/NCT01601080 Completed Merck KGaA, Darmstadt, Germany 2012-10-31
NCT01596881 Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01596881 Completed Oregon Health and Science University 2017-02-08
NCT01587690 Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells https://ClinicalTrials.gov/show/NCT01587690 Completed Rutgers, The State University of New Jersey 2013-01-31
NCT01592552 A Biospecimen and Clinical Data Study on Patients With Alzheimer’s, Multiple Sclerosis, Parkinson’s, and Huntington’s, for Drug & Biomarker Discovery https://ClinicalTrials.gov/show/NCT01592552 Completed Sanguine Biosciences 2015-03-31
NCT01592474 Evaluation of Brain Atrophy in CIS Patients on Avonex https://ClinicalTrials.gov/show/NCT01592474 Completed University at Buffalo 2011-08-31
NCT01592097 Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS https://ClinicalTrials.gov/show/NCT01592097 Completed University of Southern California 2018-04-30
NCT01547351 Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire https://ClinicalTrials.gov/show/NCT01547351 Completed Mallinckrodt 2012-09-30
NCT01547234 Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01547234 Completed Carmel Medical Center 2014-12-31
NCT01535664 An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01535664 Completed Acorda Therapeutics 2012-05-31
NCT01492023 The Effects of Attention Retraining in MS https://ClinicalTrials.gov/show/NCT01492023 Completed Finnish MS Society 2012-04-30
NCT01491100 Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01491100 Completed Bayer 2016-12-22
NCT01489748 Canadian Avonex PEN Productivity Study https://ClinicalTrials.gov/show/NCT01489748 Completed Biogen 2014-10-31
NCT01480063 An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice https://ClinicalTrials.gov/show/NCT01480063 Completed Biogen 2019-02-08
NCT01485003 Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants https://ClinicalTrials.gov/show/NCT01485003 Completed Biogen 2018-11-26
NCT01456416 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities https://ClinicalTrials.gov/show/NCT01456416 Completed University of Southern California 2013-04-30
NCT01442194 Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies https://ClinicalTrials.gov/show/NCT01442194 Recruiting Novartis NA
NCT01436838 China Betaferon Adherence, Coping and Nurse Support Study https://ClinicalTrials.gov/show/NCT01436838 Completed Bayer 2015-09-30
NCT01414816 Betaferon® Regulatory Post-Marketing Surveillance https://ClinicalTrials.gov/show/NCT01414816 Completed Bayer 2012-07-31
NCT01405872 Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. https://ClinicalTrials.gov/show/NCT01405872 Completed Biogen 2013-09-30
NCT01396343 Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01396343 Completed University of California, San Francisco 2018-04-30
NCT01399957 Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01399957 Completed Mount Sinai Rehabilitation Hospital 2014-09-30
NCT01384825 Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases https://ClinicalTrials.gov/show/NCT01384825 Completed Fondazione Italiana Sclerosi Multipla 2012-09-30
NCT01366040 Avonex PEN Satisfaction and Patients Experience Clinical Trial https://ClinicalTrials.gov/show/NCT01366040 Completed Biogen 2012-05-31
NCT01366027 PRISM Registry: Pseudobulbar Affect Registry Series https://ClinicalTrials.gov/show/NCT01366027 Completed Avanir Pharmaceuticals 2012-09-30
NCT03787446 PET Study in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03787446 Recruiting University of British Columbia 2020-03-31
NCT01356134 Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) https://ClinicalTrials.gov/show/NCT01356134 Completed Genetic Disease Investigators 2015-04-30
NCT01353547 Genes and Environment in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01353547 Recruiting Columbia University 2040-10-31
NCT01354665 Depression and Fatigue in MS Patients Treated With Betaferon. https://ClinicalTrials.gov/show/NCT01354665 Completed Bayer 2013-06-30
NCT01335633 Psychometric Validation of Cognitive Endpoints https://ClinicalTrials.gov/show/NCT01335633 Completed Kessler Foundation 2011-08-31
NCT01330498 Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical https://ClinicalTrials.gov/show/NCT01330498 Completed Rocky Mountain MS Research Group, LLC 2011-08-31
NCT04450030 Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04450030 Recruiting University Hospital Muenster 2020-08-31
NCT04438954 Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels https://ClinicalTrials.gov/show/NCT04438954 Completed Ankara Yildirim Beyazıt University 2020-06-05
NCT04408742 Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04408742 Completed Ankara Yildirim Beyazıt University 2019-10-20
NCT04390126 COVID-19 Related Lockdown Effects On Chronic Diseases https://ClinicalTrials.gov/show/NCT04390126 Active, not recruiting Centre Hospitalier Universitaire Dijon 2021-05-07
NCT04403594 Functional Intermuscular Reduction of Spasticity https://ClinicalTrials.gov/show/NCT04403594 Recruiting University of Oklahoma 2020-12-18
NCT04386863 Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study https://ClinicalTrials.gov/show/NCT04386863 Recruiting Fondazione Don Carlo Gnocchi Onlus 2020-07-07
NCT04355611 Epidemiological Characteristics of COVID-19 in Patients With MS or NMO https://ClinicalTrials.gov/show/NCT04355611 Recruiting Assistance Publique - Hôpitaux de Paris 2022-04-20
NCT04306939 Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study https://ClinicalTrials.gov/show/NCT04306939 Recruiting University of Pittsburgh 2025-12-01
NCT04300868 Immunisation Status and Safety of Vaccines in Italian MS Patients https://ClinicalTrials.gov/show/NCT04300868 Enrolling by invitation University of Siena 2020-12-31
NCT04288011 Validation of the BeCare Multiple Sclerosis Assessment App https://ClinicalTrials.gov/show/NCT04288011 Enrolling by invitation BeCare Link LLC 2021-08-26
NCT04286828 Position Sense, Balance, and Dual Task Performance at the Menstrual Cycle in Females With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04286828 Completed Ankara Yildirim Beyazıt University 2019-10-20
NCT04283071 Kinematic Assessment In Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04283071 Recruiting The Leeds Teaching Hospitals NHS Trust 2021-05-01
NCT04281160 Patient Centered Outcomes Analysis for MS Using a Mobile Application https://ClinicalTrials.gov/show/NCT04281160 Enrolling by invitation BeCare Link LLC 2020-09-01
NCT04265092 Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04265092 Completed Pôle Saint Hélier 2014-03-31
NCT04252599 Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients. https://ClinicalTrials.gov/show/NCT04252599 Recruiting Universidad de Granada 2019-12-02
NCT04240379 Metacognition Assessment in Patient With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04240379 Recruiting University Hospital, Grenoble 2021-08-31
NCT04239820 Effect of Cladribine Treatment on Microglial Activation in the CNS https://ClinicalTrials.gov/show/NCT04239820 Recruiting Turku University Hospital 2023-08-31
NCT04231253 MUltiple Sclerosis : T Cell / B Cell Exploration https://ClinicalTrials.gov/show/NCT04231253 Recruiting Rennes University Hospital 2023-02-28
NCT04228328 Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04228328 Recruiting Haute Ecole de Santé Vaud 2021-01-30
NCT04221191 Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP https://ClinicalTrials.gov/show/NCT04221191 Recruiting Biogen 2021-08-19
NCT04210960 Correlation of Serum Lactate and Activity of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04210960 Recruiting Mansoura University Hospital 2020-05-01
NCT04202055 Immunologic Biomarker Profile of Cerebrospinal Fluid https://ClinicalTrials.gov/show/NCT04202055 Completed Centre Hospitalier Universitaire de Nīmes 2019-08-31
NCT04183751 The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients https://ClinicalTrials.gov/show/NCT04183751 Recruiting Marmara University 2020-04-21
NCT04185792 Polish Translation and Validation of NBSS, Qualiveen and SF-Qualiveen https://ClinicalTrials.gov/show/NCT04185792 Recruiting Jagiellonian University 2020-09-18
NCT04153773 OCT and Early Cognitive Impairment in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04153773 Completed Mansoura University Hospital 2019-06-01
NCT04148313 A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04148313 Recruiting ProgenaBiome 2023-03-31
NCT04133779 Observational Study on Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04133779 Completed Fondazione Italiana Sclerosi Multipla 2012-05-30
NCT04132037 An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT04132037 Active, not recruiting University Hospital, Toulouse 2021-12-31
NCT04131764 Diagnosis of ON With or Without MS or NMOSD https://ClinicalTrials.gov/show/NCT04131764 Enrolling by invitation University of Kentucky 2021-12-31
NCT04131673 MS and NMOSD in African-Americans https://ClinicalTrials.gov/show/NCT04131673 Enrolling by invitation University of Kentucky 2023-12-31
NCT04126772 Multimodal Imaging of MS Reveals the Smoldering Inflammation https://ClinicalTrials.gov/show/NCT04126772 Recruiting Turku University Hospital 2022-01-31
NCT04123353 Scan-Rescan Sub-Study of MS PATHS https://ClinicalTrials.gov/show/NCT04123353 Completed Biogen 2017-05-09
NCT04114994 Longitudinal Cognitive Assessment by BoCA https://ClinicalTrials.gov/show/NCT04114994 Recruiting Alzheimer’s Light LLC 2029-10-01
NCT04115930 Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients https://ClinicalTrials.gov/show/NCT04115930 Completed University of Eastern Finland 2019-06-13
NCT04095377 Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019. https://ClinicalTrials.gov/show/NCT04095377 Active, not recruiting QuantalX Neuroscience 2020-03-31
NCT04082468 VALIDATE: Factor VIII Trending for MS Relapse https://ClinicalTrials.gov/show/NCT04082468 Recruiting St. Joseph’s Hospital and Medical Center, Phoenix 2021-12-01
NCT04080687 Effect of Ankle-foot Orthoses on Balance Confidence https://ClinicalTrials.gov/show/NCT04080687 Recruiting University Rehabilitation Institute, Republic of Slovenia 2020-05-31
NCT04075968 The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS https://ClinicalTrials.gov/show/NCT04075968 Completed Istanbul Physical Medicine Rehabilitation Training and Research Hospital 2019-11-15
NCT04082260 Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response https://ClinicalTrials.gov/show/NCT04082260 Recruiting University Hospital Muenster 2022-01-31
NCT04063852 PTNS on Urinary and Global Quality of Life in MS Patients https://ClinicalTrials.gov/show/NCT04063852 Recruiting University of Michigan 2021-12-31
NCT04057222 Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04057222 Completed Pierre and Marie Curie University 2019-09-06
NCT04053374 Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04053374 Recruiting University College, London 2020-06-30
NCT04024969 DiagnosE Using the Central veIn SIgn https://ClinicalTrials.gov/show/NCT04024969 Recruiting Nottingham University Hospitals NHS Trust 2022-05-31
NCT04024085 Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04024085 Recruiting Pierre and Marie Curie University 2019-07-31
NCT04022564 Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04022564 Active, not recruiting China Medical University Hospital 2020-05-20
NCT03347370 A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03347370 Completed Biogen 2019-07-31
NCT03993275 Exergames Balance Program in Neurorehabilitation https://ClinicalTrials.gov/show/NCT03993275 Completed Klinik Valens 2020-01-15
NCT03981003 Serum Neurofilament-light Chain Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03981003 Recruiting Centre Hospitalier Universitaire de Nīmes 2023-06-30
NCT03963310 Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03963310 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2024-05-31
NCT03945006 Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence https://ClinicalTrials.gov/show/NCT03945006 Completed Ankara Yildirim Beyazıt University 2019-04-20
NCT03942952 PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. https://ClinicalTrials.gov/show/NCT03942952 Recruiting University of Texas Southwestern Medical Center 2022-05-31
NCT03933215 A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) https://ClinicalTrials.gov/show/NCT03933215 Recruiting EMD Serono 2023-11-29
NCT03933202 A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) https://ClinicalTrials.gov/show/NCT03933202 Recruiting EMD Serono 2023-05-03
NCT03927092 Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire https://ClinicalTrials.gov/show/NCT03927092 Completed Ege University 2016-05-31
NCT03917589 Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS) https://ClinicalTrials.gov/show/NCT03917589 Recruiting Rennes University Hospital 2021-06-20
NCT03893344 STAT4 in Multiple Sclerosis by PCR and Flow Cytometry https://ClinicalTrials.gov/show/NCT03893344 Completed Assiut University 2020-05-20
NCT03873389 Ocrelizumab Effects on the Metabolome in MS https://ClinicalTrials.gov/show/NCT03873389 Recruiting Johns Hopkins University 2023-01-31
NCT03886753 Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products https://ClinicalTrials.gov/show/NCT03886753 Active, not recruiting Children’s Hospital of Philadelphia 2020-12-31
NCT03863379 Sarcopenic Obesity in Neurodisabilities https://ClinicalTrials.gov/show/NCT03863379 Enrolling by invitation Dionyssiotis, Yannis, M.D. 2021-05-31
NCT03067025 Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03067025 Completed The Hospital for Sick Children 2019-09-16
NCT03854123 Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics https://ClinicalTrials.gov/show/NCT03854123 Recruiting University Hospital, Bordeaux 2020-12-31
NCT03841903 Spinal Cord Analysis in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03841903 Completed University Hospital, Basel, Switzerland 2020-03-24
NCT03806387 Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment https://ClinicalTrials.gov/show/NCT03806387 Recruiting University of Aarhus 2019-04-30
NCT03808142 PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon https://ClinicalTrials.gov/show/NCT03808142 Completed Bayer 2020-04-20
NCT03796247 Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event https://ClinicalTrials.gov/show/NCT03796247 Completed University Hospital, Lille 2016-05-31
NCT03784547 Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM https://ClinicalTrials.gov/show/NCT03784547 Recruiting Hospital Italiano de Buenos Aires 2019-08-01
NCT03757065 Cell Surface Marker Expression in Autoimmune Diseases https://ClinicalTrials.gov/show/NCT03757065 Enrolling by invitation Alpine Immune Sciences, Inc. 2020-03-31
NCT03756142 Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT03756142 Recruiting Lille Catholic University 2020-11-05
NCT03736902 Views on Physical Activity Following a Relapse in People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03736902 Completed City, University of London 2019-05-14
NCT03723356 Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT03723356 Recruiting NYU Langone Health 2021-12-13
NCT03718026 The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03718026 Completed Gazi University 2018-11-16
NCT03718247 Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS https://ClinicalTrials.gov/show/NCT03718247 Recruiting University of Virginia 2022-10-31
NCT03703180 Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS https://ClinicalTrials.gov/show/NCT03703180 Recruiting Universitätsklinikum Hamburg-Eppendorf 2021-02-28
NCT03656055 Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03656055 Recruiting University Hospital, Lille 2019-12-31
NCT03655093 Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03655093 Completed Rennes University Hospital 2017-07-03
NCT03653585 Cortical Lesions in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03653585 Recruiting Danish Research Centre for Magnetic Resonance 2020-07-31
NCT03647722 Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab). https://ClinicalTrials.gov/show/NCT03647722 Recruiting University of Southern California 2022-09-30
NCT03632473 Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03632473 Recruiting University Hospital, Basel, Switzerland 2022-07-31
NCT03597451 The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03597451 Completed Gazi University 2020-02-28
NCT03594357 Cognitive Functions in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03594357 Completed Gazi University 2018-12-21
NCT03586986 Risk Factors in Early Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03586986 Recruiting University of Colorado, Denver 2020-05-30
NCT03593590 Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03593590 Recruiting Hoffmann-La Roche 2025-07-26
NCT03577977 Betaferon Use in Children and Adolescents With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03577977 Completed Bayer 2009-04-15
NCT03561402 Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) https://ClinicalTrials.gov/show/NCT03561402 Recruiting McGill University 2018-08-30
NCT03562975 Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus https://ClinicalTrials.gov/show/NCT03562975 Recruiting University of South Florida 2020-08-31
NCT03541226 Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS) https://ClinicalTrials.gov/show/NCT03541226 Recruiting University Hospital, Lille 2021-09-30
NCT03508284 Dual-Task Performance in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03508284 Completed Gazi University 2019-05-16
NCT03464448 Mechanistic Studies of Teriflunomide in RRMS https://ClinicalTrials.gov/show/NCT03464448 Recruiting University of Michigan 2021-10-31
NCT03451175 Reproductibility of Cystometry in Multiple Sclerosis Patient https://ClinicalTrials.gov/show/NCT03451175 Completed Pierre and Marie Curie University 2017-11-01
NCT03438357 Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI https://ClinicalTrials.gov/show/NCT03438357 Active, not recruiting Centre Hospitalier Universitaire de Nīmes 2020-11-30
NCT01271699 Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01271699 Completed Centogene AG Rostock 2019-12-01
NCT01233245 BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program https://ClinicalTrials.gov/show/NCT01233245 Completed Bayer 2009-06-30
NCT01235455 Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors https://ClinicalTrials.gov/show/NCT01235455 Completed Bayer NA
NCT01206023 Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples https://ClinicalTrials.gov/show/NCT01206023 Completed Carmel Medical Center 2011-11-30
NCT01207648 Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) https://ClinicalTrials.gov/show/NCT01207648 Completed EMD Serono 2011-07-31
NCT01195870 Assessment of Patient Use of a New Device: RebiSmart https://ClinicalTrials.gov/show/NCT01195870 Completed Merck KGaA, Darmstadt, Germany 2010-09-30
NCT01195857 Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration https://ClinicalTrials.gov/show/NCT01195857 Completed Merck KGaA, Darmstadt, Germany 2009-09-30
NCT01185717 JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01185717 Completed Biogen 2012-05-31
NCT01184833 Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01184833 Completed Bayer NA
NCT01158183 Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01158183 Completed Bayer 2009-09-30
NCT01157728 Early Cognitive Impairment in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01157728 Completed Assistance Publique - Hôpitaux de Paris 2010-12-31
NCT01142583 A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01142583 Completed Merck KGaA, Darmstadt, Germany 2009-08-31
NCT01142557 An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01142557 Completed Merck KGaA, Darmstadt, Germany 2005-11-30
NCT01142518 An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone https://ClinicalTrials.gov/show/NCT01142518 Completed Merck KGaA, Darmstadt, Germany 2009-03-31
NCT01142492 A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) https://ClinicalTrials.gov/show/NCT01142492 Completed Merck KGaA, Darmstadt, Germany 2008-07-31
NCT01141751 An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy https://ClinicalTrials.gov/show/NCT01141751 Completed Merck KGaA, Darmstadt, Germany 2011-06-30
NCT01142453 An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients https://ClinicalTrials.gov/show/NCT01142453 Completed Merck KGaA, Darmstadt, Germany 2008-06-30
NCT01128075 Treatment Adherence When Using RebiSmartâ„¢ in Relapsing Multiple Sclerosis Subjects https://ClinicalTrials.gov/show/NCT01128075 Completed Merck KGaA, Darmstadt, Germany 2014-04-30
NCT01125475 A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects https://ClinicalTrials.gov/show/NCT01125475 Completed Merck KGaA, Darmstadt, Germany 2012-03-31
NCT01118130 Pharmacogenomics of Drug Safety in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01118130 Recruiting University of British Columbia 2020-12-31
NCT01112657 An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period https://ClinicalTrials.gov/show/NCT01112657 Completed Merck KGaA, Darmstadt, Germany 2014-10-31
NCT01117090 Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery https://ClinicalTrials.gov/show/NCT01117090 Completed MedtronicNeuro 2012-09-30
NCT01112345 An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters https://ClinicalTrials.gov/show/NCT01112345 Completed Merck KGaA, Darmstadt, Germany 2012-09-30
NCT01110993 An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) https://ClinicalTrials.gov/show/NCT01110993 Completed Merck KGaA, Darmstadt, Germany 2013-09-30
NCT01108887 An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. https://ClinicalTrials.gov/show/NCT01108887 Completed Merck KGaA, Darmstadt, Germany 2013-01-31
NCT01101776 Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. https://ClinicalTrials.gov/show/NCT01101776 Completed Merck KGaA, Darmstadt, Germany 2013-04-30
NCT01084798 A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years https://ClinicalTrials.gov/show/NCT01084798 Completed Merck KGaA, Darmstadt, Germany 2008-12-31
NCT01080573 Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01080573 Completed Merck KGaA, Darmstadt, Germany 2011-04-30
NCT01080053 Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01080053 Completed Merck KGaA, Darmstadt, Germany 2013-05-31
NCT01080040 To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01080040 Completed Merck KGaA, Darmstadt, Germany 2013-03-31
NCT01076595 Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period https://ClinicalTrials.gov/show/NCT01076595 Completed Bayer 2013-11-30
NCT01080027 Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) https://ClinicalTrials.gov/show/NCT01080027 Completed Merck KGaA, Darmstadt, Germany 2011-06-30
NCT01075880 Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® https://ClinicalTrials.gov/show/NCT01075880 Completed Merck KGaA, Darmstadt, Germany 2013-06-30
NCT01080014 Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina https://ClinicalTrials.gov/show/NCT01080014 Completed Merck KGaA, Darmstadt, Germany 2013-04-30
NCT01080001 A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina https://ClinicalTrials.gov/show/NCT01080001 Completed Merck KGaA, Darmstadt, Germany 2010-12-31
NCT01075737 An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers https://ClinicalTrials.gov/show/NCT01075737 Completed Merck KGaA, Darmstadt, Germany 2011-03-31
NCT01079975 To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01079975 Completed Merck KGaA, Darmstadt, Germany 2010-10-31
NCT01074346 Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01074346 Completed Merck KGaA, Darmstadt, Germany 2011-11-30
NCT01070836 JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab https://ClinicalTrials.gov/show/NCT01070836 Completed Biogen 2015-11-30
NCT01070823 JC-Virus (JCV) Antibody Program https://ClinicalTrials.gov/show/NCT01070823 Completed Biogen 2012-06-30
NCT01067573 The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment https://ClinicalTrials.gov/show/NCT01067573 Completed University of South Florida NA
NCT01070719 Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort https://ClinicalTrials.gov/show/NCT01070719 Completed Rocky Mountain MS Research Group, LLC 2010-05-31
NCT01065090 A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01065090 Completed Biogen 2014-01-31
NCT01044576 Patient Research Cohort: Rapidly Evolving Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01044576 Completed Imperial College London 2012-11-30
NCT01034644 Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15) https://ClinicalTrials.gov/show/NCT01034644 Completed Merck KGaA, Darmstadt, Germany 2010-11-30
NCT01020370 Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies https://ClinicalTrials.gov/show/NCT01020370 Completed Wayne State University NA
NCT01013350 Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials https://ClinicalTrials.gov/show/NCT01013350 Completed EMD Serono 2018-10-25
NCT00963833 Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00963833 Completed Bayer 2016-04-12
NCT00937677 Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study https://ClinicalTrials.gov/show/NCT00937677 Completed University at Buffalo 2009-12-31
NCT00928967 Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT00928967 Completed Bayer 2010-03-31
NCT00919217 Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms https://ClinicalTrials.gov/show/NCT00919217 Recruiting University of Louisville 2020-12-31
NCT00902135 Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) https://ClinicalTrials.gov/show/NCT00902135 Completed Bayer 2013-12-31
NCT00888277 Bayer/Cognitive Assessments With Multiple Sclerosis Subjects https://ClinicalTrials.gov/show/NCT00888277 Completed University of Louisville 2009-12-31
NCT00884481 Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS https://ClinicalTrials.gov/show/NCT00884481 Completed Biogen 2011-06-30
NCT00883142 Functional and Physiological Responses to Lokomat Therapy (Pilot Study) https://ClinicalTrials.gov/show/NCT00883142 Completed VA Office of Research and Development 2012-08-31
NCT00882453 Physical Activity and Fatigue in Early Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00882453 Completed Bayer 2011-03-31
NCT00873340 Physical Disability in Patients Treated With Betaferon https://ClinicalTrials.gov/show/NCT00873340 Completed Bayer 2011-01-31
NCT00859482 Differential Immune Effects of Natalizumab https://ClinicalTrials.gov/show/NCT00859482 Completed Cantonal Hospital of St. Gallen 2007-07-31
NCT04338646 Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04338646 Recruiting Pierre and Marie Curie University 2020-04-15
NCT04157283 Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities https://ClinicalTrials.gov/show/NCT04157283 Recruiting Mansoura University Hospital 2020-05-05
NCT03926637 Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03926637 Recruiting Biogen 2022-09-01
NCT02880553 Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02880553 Completed Fondation Ophtalmologique Adolphe de Rothschild 2017-03-09
NCT01031459 Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial. https://ClinicalTrials.gov/show/NCT01031459 Completed Bayer 2010-12-31
NCT02021162 Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02021162 Completed University at Buffalo 2018-09-30
NCT03686826 Feasibility and Reliability of Multimodal Evoked Potentials https://ClinicalTrials.gov/show/NCT03686826 Completed University Hospital, Basel, Switzerland 2017-09-15
NCT02823951 Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® https://ClinicalTrials.gov/show/NCT02823951 Completed IMS HEALTH GmbH & Co. OHG 2017-04-30
NCT00812474 Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00812474 Completed Sunnybrook Health Sciences Centre 2009-06-30
NCT01706055 Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) https://ClinicalTrials.gov/show/NCT01706055 Completed Bayer 2015-09-30
NCT01766063 Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon https://ClinicalTrials.gov/show/NCT01766063 Completed Bayer 2017-01-09
NCT03954717 Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program https://ClinicalTrials.gov/show/NCT03954717 Enrolling by invitation Shepherd Center, Atlanta GA 2021-07-28
NCT03332654 Stress Urinary Incontinence in Women With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03332654 Completed Lille Catholic University 2016-01-31
NCT03134716 Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03134716 Active, not recruiting Turku University Hospital 2022-04-30
NCT03187847 Rehabilitation in Multiple Sclerosis - Sometimes Too Much? https://ClinicalTrials.gov/show/NCT03187847 Completed Klinik Valens 2018-03-30
NCT02686684 Tecfidera Diffusion Tensor Imaging https://ClinicalTrials.gov/show/NCT02686684 Completed University at Buffalo 2016-10-31
NCT02836327 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders https://ClinicalTrials.gov/show/NCT02836327 Recruiting Chinese PLA General Hospital 2019-09-30
NCT02598167 Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition https://ClinicalTrials.gov/show/NCT02598167 Completed Hoffmann-La Roche 2016-02-23
NCT01804660 Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population https://ClinicalTrials.gov/show/NCT01804660 Completed GeNeuro Innovation SAS 2013-11-30
NCT01804647 Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease https://ClinicalTrials.gov/show/NCT01804647 Completed GeNeuro Innovation SAS 2015-02-28
NCT04371575 Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients https://ClinicalTrials.gov/show/NCT04371575 Completed Danish Headache Center 2019-12-31
NCT01658384 Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01658384 Completed Clinique Neuro-Outaouais 2015-02-28
NCT03941184 Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity https://ClinicalTrials.gov/show/NCT03941184 Recruiting Mayo Clinic 2020-12-31
NCT03486665 Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients. https://ClinicalTrials.gov/show/NCT03486665 Recruiting Bioimmunate 2018-09-30
NCT00787657 Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment https://ClinicalTrials.gov/show/NCT00787657 Completed Bayer 2013-09-30
NCT00715598 Cognitive Testing for the Pain Quality Assessment Scale (PQAS) https://ClinicalTrials.gov/show/NCT00715598 Completed University of Washington 2010-06-30
NCT00704834 Gene Expression Profiles in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00704834 Completed University of California, Davis 2017-07-05
NCT00710645 Lido Workset Study https://ClinicalTrials.gov/show/NCT00710645 Completed University of California, Davis 2012-06-30
NCT00704626 Serum Auto-Antibodies in Neurological Diseases https://ClinicalTrials.gov/show/NCT00704626 Enrolling by invitation University of California, Davis 2020-12-31
NCT00702065 A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment https://ClinicalTrials.gov/show/NCT00702065 Completed EMD Serono 2010-10-31
NCT00675883 COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS https://ClinicalTrials.gov/show/NCT00675883 Completed Biogen 2011-12-31
NCT00618267 ATP Expression in Lymphocytes of MS Patients by Means of “ImmuKnow®” Assay. https://ClinicalTrials.gov/show/NCT00618267 Completed Biogen 2008-12-31
NCT00617383 AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS https://ClinicalTrials.gov/show/NCT00617383 Completed The University of Texas Health Science Center, Houston 2010-12-31
NCT00599274 Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00599274 Completed Biogen NA
NCT00544037 BENEFIT Extension Study https://ClinicalTrials.gov/show/NCT00544037 Completed Bayer 2011-01-31
NCT00525343 Avonex 15 Year Long Term Follow-up Study https://ClinicalTrials.gov/show/NCT00525343 Completed Biogen NA
NCT00492570 GER-009-06-AVX Early Therapy in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00492570 Completed Biogen 2007-10-31
NCT00490906 Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00490906 Completed University of Kansas Medical Center 2009-02-28
NCT00483847 TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World https://ClinicalTrials.gov/show/NCT00483847 Completed Biogen 2014-11-30
NCT00477113 TYSABRI Global Observational Program in Safety https://ClinicalTrials.gov/show/NCT00477113 Completed Biogen 2015-05-31
NCT00468182 Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00468182 Completed Rutgers, The State University of New Jersey 2011-12-31
NCT00461396 Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron https://ClinicalTrials.gov/show/NCT00461396 Completed Bayer 2009-06-30
NCT00464074 Evaluation of Natalizumab for thE Relief of MS Associated FatiGue https://ClinicalTrials.gov/show/NCT00464074 Completed Biogen 2010-07-31
NCT00463710 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS https://ClinicalTrials.gov/show/NCT00463710 Completed State University of New York at Buffalo NA
NCT00445367 Biobank For MS And Other Demyelinating Diseases https://ClinicalTrials.gov/show/NCT00445367 Active, not recruiting Accelerated Cure Project for Multiple Sclerosis 2026-10-31
NCT00439257 Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron) https://ClinicalTrials.gov/show/NCT00439257 Completed VA Office of Research and Development NA
NCT00430599 The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00430599 Completed Newcastle-upon-Tyne Hospitals NHS Trust NA
NCT00424359 Ambulation Study in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00424359 Completed Brown, Theodore R., M.D., MPH NA
NCT00393588 Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00393588 Completed National Institutes of Health Clinical Center (CC) NA
NCT00391352 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls https://ClinicalTrials.gov/show/NCT00391352 Completed Waukesha Memorial Hospital 2012-08-31
NCT00338741 Rebif® Pregnancy Registry https://ClinicalTrials.gov/show/NCT00338741 Completed EMD Serono 2007-10-31
NCT00336557 Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy https://ClinicalTrials.gov/show/NCT00336557 Completed Teva Pharmaceutical Industries 2009-04-30
NCT00325988 Biomarkers in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00325988 Completed National Institutes of Health Clinical Center (CC) NA
NCT00317564 Betaseron Pregnancy Registry https://ClinicalTrials.gov/show/NCT00317564 Completed Syneos Health 2012-04-30
NCT00321568 Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00321568 Completed National Institutes of Health Clinical Center (CC) NA
NCT00288990 A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00288990 Completed Biogen NA
NCT00262314 Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT00262314 Completed EMD Serono 2008-01-31
NCT00238654 A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy https://ClinicalTrials.gov/show/NCT00238654 Completed Teva Pharmaceutical Industries 2008-07-31
NCT00232193 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS https://ClinicalTrials.gov/show/NCT00232193 Completed Providence Multiple Sclerosis Center 2008-12-31
NCT00229502 Cognitive Effects of Immunomodulatory Drugs in MS https://ClinicalTrials.gov/show/NCT00229502 Completed University of Kansas Medical Center 2011-09-30
NCT00223457 Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00223457 Completed University of Texas Southwestern Medical Center NA
NCT00206635 Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00206635 Completed Bayer NA
NCT00203086 A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00203086 Completed Teva Pharmaceutical Industries 2009-10-31
NCT00168714 Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) https://ClinicalTrials.gov/show/NCT00168714 Completed Biogen 2011-09-30
NCT00099307 Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00099307 Completed National Institutes of Health Clinical Center (CC) NA
NCT00094068 The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT00094068 Completed National Institutes of Health Clinical Center (CC) NA
NCT00819195 Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00819195 Completed University of California, San Francisco 2012-09-30
NCT00819000 Therapy Optimization in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00819000 Completed Teva Pharmaceutical Industries 2012-12-31
NCT00064909 MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00064909 Completed National Institutes of Health Clinical Center (CC) NA
NCT00818038 A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function https://ClinicalTrials.gov/show/NCT00818038 Completed Biogen 2011-03-31
NCT00001156 Assessment of Patients With Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00001156 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03375177 Multiple Sclerosis Registry in Argentina (RelevarEM) https://ClinicalTrials.gov/show/NCT03375177 Recruiting Hospital Italiano de Buenos Aires 2021-07-16
NCT03247894 Obstetric Anesthesia and Analgesia and Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03247894 Completed Brno University Hospital 2017-07-31
NCT03215433 Study of Biomarkers of the Response to Biotine https://ClinicalTrials.gov/show/NCT03215433 Completed Centre Hospitalier Universitaire Dijon 2019-01-23
NCT03198351 An Observational Study on Teriflunomide-exposed Pregnancies https://ClinicalTrials.gov/show/NCT03198351 Recruiting Sanofi 2022-02-01
NCT03193866 COMparison Between All immunoTherapies for Multiple Sclerosis. https://ClinicalTrials.gov/show/NCT03193866 Active, not recruiting Karolinska Institutet 2022-06-30
NCT02980640 Swiss Multiple Sclerosis Registry https://ClinicalTrials.gov/show/NCT02980640 Recruiting Swiss Multiple Sclerosis Registry 2041-06-30
NCT02970370 Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt https://ClinicalTrials.gov/show/NCT02970370 Completed Cairo University 2016-07-31
NCT02883335 Lorraine Registry of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02883335 Recruiting Central Hospital, Nancy, France 2020-01-31
NCT02848976 Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life https://ClinicalTrials.gov/show/NCT02848976 Completed Nantes University Hospital 2010-04-30
NCT02633033 Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse https://ClinicalTrials.gov/show/NCT02633033 Completed Mallinckrodt 2019-05-09
NCT02073474 An Observational Post-Marketing Safety Registry of Sativex® https://ClinicalTrials.gov/show/NCT02073474 Completed GW Pharmaceuticals Ltd. 2015-01-31
NCT02047097 Dimethyl Fumarate (DMF) Observational Study https://ClinicalTrials.gov/show/NCT02047097 Recruiting Biogen 2024-02-28
NCT02004444 JC Virus Reactivation in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02004444 Completed Beth Israel Deaconess Medical Center 2016-01-31
NCT01952483 Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients https://ClinicalTrials.gov/show/NCT01952483 Completed American University of Beirut Medical Center 2017-05-01
NCT01911767 Biogen Multiple Sclerosis Pregnancy Exposure Registry https://ClinicalTrials.gov/show/NCT01911767 Recruiting Biogen 2028-05-31
NCT04380220 Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04380220 Active, not recruiting Regina Elena Cancer Institute 2020-08-31
NCT04354519 The United Kingdom Multiple Sclerosis Register Covid-19 Substudy https://ClinicalTrials.gov/show/NCT04354519 Recruiting Swansea University 2021-07-14
NCT04289675 Multiple Sclerosis: Chi3L1 and Treatment Efficacy https://ClinicalTrials.gov/show/NCT04289675 Completed Central Hospital, Nancy, France 2019-12-01
NCT04237675 Postoperative Relapses in MS Patients https://ClinicalTrials.gov/show/NCT04237675 Recruiting University of Athens 2027-12-31
NCT04182269 Reliability and Validity of Glittre Activities Of Daily Living (ADL) Test in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT04182269 Completed Hacettepe University 2019-10-15
NCT04106830 Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE) https://ClinicalTrials.gov/show/NCT04106830 Recruiting Beijing Tiantan Hospital 2022-12-31
NCT04028232 Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS). https://ClinicalTrials.gov/show/NCT04028232 Recruiting University Hospital, Caen 2020-04-30
NCT04004026 3 Meter Backwards Walk Test and Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04004026 Recruiting Sanko University 2019-06-15
NCT03906370 Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS https://ClinicalTrials.gov/show/NCT03906370 Active, not recruiting University of Aarhus 2021-03-01
NCT03900221 French Registry for Monitoring Pregnancies for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03900221 Recruiting Hospices Civils de Lyon 2030-08-12
NCT03847753 Exploring the Comorbidity Between Mental Disorders and General Medical Conditions https://ClinicalTrials.gov/show/NCT03847753 Completed University of Aarhus 2016-12-31
NCT03774914 LEMTRADA Pregnancy Registry in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03774914 Recruiting Sanofi 2022-11-30
NCT03766698 Muscle Architecture of Lower Extremity In Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03766698 Completed Sanko University 2020-01-18
NCT03735823 IL-11 in the Development of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03735823 Recruiting Thomas Jefferson University 2023-05-31
NCT03603457 OFSEP High Definition Cohort https://ClinicalTrials.gov/show/NCT03603457 Recruiting EDMUS Foundation 2020-12-31
NCT03552185 Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies https://ClinicalTrials.gov/show/NCT03552185 Completed Kasr El Aini Hospital 2018-06-15
NCT03456206 Chronic Inflammatory Disease, Lifestyle and Risk of Disease https://ClinicalTrials.gov/show/NCT03456206 Active, not recruiting University of Southern Denmark 2019-07-01
NCT01018537 NARCOMS Registry: A Multiple Sclerosis Registry https://ClinicalTrials.gov/show/NCT01018537 Recruiting Washington University School of Medicine 2050-12-31
NCT03878836 Follow-up of Persons With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03878836 Recruiting Dokuz Eylul University 2021-08-01
NCT00472992 Pregnancy Exposure Registry for Tysabri® https://ClinicalTrials.gov/show/NCT00472992 Completed Biogen 2012-07-31